\-\ Texto\\:\\ \ \(0\)\
\-\ slender\\ male\\,\\ currently\\ asymptomatic\\.\ \(0\)\
\-\ thus\\ far\\,\\ this\\ patient\\ has\\ been\\ received\\ medical\\ therapy\\ only\\.\\ \\ interval\\ clinical\\ and\\ radiologic\\ reevaluation\\ is\\ planned\\,\\ with\\ the\\ reevaluation\\ interval\\ to\\ be\\ determined\\ based\\ on\\ symptoms\\ and\\ disease\\ progression\\.\ \(0\)\
\-\ several\\ regions\\ of\\ discontinuous\\ and\\ asymmetric\\ bowel\\ wall\\ thickening\\ with\\ alternating\\ regions\\ of\\ dilation\\.\\ \\ no\\ fistulas\\ were\\ identified\\ in\\ this\\ patient\\‚\\Ä\\ôs\\ case\\.\\ \\ enhancement\\ localized\\ to\\ the\\ regions\\ of\\ mural\\ thickening\\ was\\ demonstrated\\ following\\ the\\ administration\\ of\\ intravenous\\ gadolinium\\ dtpa\\.\ \(0\)\
\-\ crohn\\ disease\ \(0\)\
\-\ \\&\\#61550\\;\\	ulcerative\\ colitis\\ \\(\\‚\\Ä\\úbackwash\\ ileitis\\‚\\Ä\\ù\\)\ \(0\)\
\-\ \\&\\#61550\\;\\	infection\ \(0\)\
\-\ \\&\\#61550\\;\\	ischemia\ \(0\)\
\-\ \\&\\#61550\\;\\	radiation\\ enteritis\ \(0\)\
\-\ \\&\\#61550\\;\\	metastases\\ \\/\\ lymphoma\ \(0\)\
\-\ 54\\ year\\-old\\ male\\ with\\ recurrent\\ abdominal\\ pain\\ and\\ diarrhea\\.\ \(1\)\
\-\ the\\ exact\\ etiology\\ of\\ crohn\\‚\\Ä\\ôs\\ disease\\ is\\ unknown\\.\\ \\ there\\ is\\ a\\ familial\\ disposition\\.\\ \\ most\\ common\\ age\\ of\\ presentation\\ is\\ 15\\-25\\ years\\,\\ with\\ an\\ equal\\ distribution\\ between\\ the\\ sexes\\.\\ \\ there\\ is\\ a\\ four\\-fold\\ increase\\ in\\ incidence\\ amongst\\ smokers\\.\\ \\ the\\ most\\ common\\ presenting\\ symptoms\\ include\\ diarrhea\\,\\ pain\\,\\ melena\\,\\ weight\\ loss\\ and\\ fever\\.\\ \\ \ \(0\)\
\-\ associated\\ abnormalities\\ include\\ arthritis\\,\\ cholelithiasis\\,\\ sclerosing\\ cholangitis\\,\\ uveitis\\ and\\ ankylosing\\ spondylitis\\.\\ \\ based\\ on\\ pathology\\,\\ there\\ are\\ three\\ stages\\ of\\ crohn\\‚\\Ä\\ôs\\ disease\\.\\ \\ the\\ early\\ stage\\ includes\\ hyperplasia\\ of\\ lymphoid\\ tissue\\ and\\ shallow\\ mucosal\\ erosions\\ \\(aphthoid\\ ulcers\\)\\.\\ \\ the\\ intermediate\\ stage\\ is\\ defined\\ by\\ transmural\\ extension\\ within\\ the\\ mucosa\\ and\\ subserosa\\ with\\ marked\\ fold\\ thickening\\.\\ \\ the\\ advanced\\ stage\\ includes\\ transmural\\ extension\\ to\\ and\\ through\\ the\\ serosa\\ and\\ deep\\ ulcerations\\ and\\ fissures\\.\ \(0\)\
\-\ lesions\\ can\\ occur\\ anywhere\\ along\\ the\\ entire\\ length\\ of\\ the\\ gut\\,\\ from\\ the\\ mouth\\ to\\ the\\ anus\\.\\ \\ the\\ terminal\\ ileum\\ and\\ proximal\\ colon\\ are\\ the\\ most\\ common\\ sites\\ of\\ involvement\\.\\ \\ skip\\ lesions\\ more\\ commonly\\ involve\\ the\\ distal\\ ileum\\.\ \(0\)\
\-\ 10\\-20\\%\\ of\\ patients\\ lead\\ symptom\\-free\\ lives\\.\\ \\ medical\\ treatment\\ includes\\ steroids\\,\\ azathioprine\\,\\ mesalamine\\,\\ and\\ antibiotics\\.\\ \\ surgical\\ treatment\\ involves\\ resection\\ of\\ the\\ affected\\ bowel\\.\\ \\ 30\\-53\\%\\ recur\\ after\\ surgical\\ resection\\.\ \(0\)\
\-\ references\\:\ \(0\)\
\-\ gore\\ rm\\,\\ et\\ al\\.\\ \\ ct\\ features\\ of\\ ulcerative\\ colitis\\ and\\ crohn\\‚\\Ä\\ôs\\ disease\\.\\ \\ am\\ j\\ roentgenl\\.\\ \\ 167\\(1\\)\\:3\\-15\\,\\ 1996\\.\ \(0\)\
\-\ hizawa\\ k\\,\\ et\\ al\\.\\ \\ crohn\\ disease\\:\\ early\\ recognition\\ and\\ progress\\ of\\ aphthous\\ lesions\\.\\ \\ radiology\\.\\ \\ 190\\(2\\)\\:451\\-4\\,\\ 1994\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ 61550\\:\\ 0\\.10803331401919729\ \(0\)\
\-\ crohn\\:\\ 0\\.05596842134702376\ \(0\)\
\-\ \\#\\:\\ 0\\.04107459091839324\ \(0\)\
\-\ reevaluation\\:\\ 0\\.037827971251462686\ \(0\)\
\-\ transmural\\:\\ 0\\.037827971251462686\ \(0\)\
\-\ \\&\\:\\ 0\\.03678171436447833\ \(0\)\
\-\ regions\\:\\ 0\\.0287517915112358\ \(0\)\
\-\ stage\\:\\ 0\\.026801723742120195\ \(0\)\
\-\ ulcerative\\:\\ 0\\.026706973499902077\ \(0\)\
\-\ includes\\:\\ 0\\.02533000291057967\ \(0\)\
\-\ \\‚\\Ä\\ô\\:\\ 0\\.02503947783966133\ \(0\)\
\-\ \\;\\:\\ 0\\.024821338093781786\ \(0\)\
\-\ s\\:\\ 0\\.02402713399131948\ \(0\)\
\-\ ileum\\:\\ 0\\.023481209476624257\ \(0\)\
\-\ colitis\\:\\ 0\\.02298227470059513\ \(0\)\
\-\ diarrhea\\:\\ 0\\.021732802888689295\ \(0\)\
\-\ four\\-fold\\:\\ 0\\.021606662803839456\ \(0\)\
\-\ aphthoid\\:\\ 0\\.021606662803839456\ \(0\)\
\-\ subserosa\\:\\ 0\\.021606662803839456\ \(0\)\
\-\ symptom\\-free\\:\\ 0\\.021606662803839456\ \(0\)\
\-\ 30\\-53\\:\\ 0\\.021606662803839456\ \(0\)\
\-\ roentgenl\\:\\ 0\\.021606662803839456\ \(0\)\
\-\ \\:3\\-15\\:\\ 0\\.021606662803839456\ \(0\)\
\-\ hizawa\\:\\ 0\\.021606662803839456\ \(0\)\
\-\ \\:451\\-4\\:\\ 0\\.021606662803839456\ \(0\)\
\-\ thickening\\:\\ 0\\.021298710071274644\ \(0\)\
\-\ interval\\:\\ 0\\.020541890248442288\ \(0\)\
\-\ disease\\:\\ 0\\.020540257959054474\ \(0\)\
\-\ slender\\:\\ 0\\.019907772655408218\ \(0\)\
\-\ backwash\\:\\ 0\\.018913985625731343\ \(0\)\
\-\ mesalamine\\:\\ 0\\.018913985625731343\ \(0\)\
\-\ gore\\:\\ 0\\.018913985625731343\ \(0\)\
\-\ 1996\\.\\:\\ 0\\.018913985625731343\ \(0\)\
\-\ aphthous\\:\\ 0\\.018913985625731343\ \(0\)\
\-\ 15\\-25\\:\\ 0\\.01820888250697698\ \(0\)\
\-\ sexes\\:\\ 0\\.01820888250697698\ \(0\)\
\-\ serosa\\:\\ 0\\.01820888250697698\ \(0\)\
\-\ al\\:\\ 0\\.0177576547699818\ \(0\)\
\-\ disposition\\:\\ 0\\.017661962038069603\ \(0\)\
\-\ amongst\\:\\ 0\\.017661962038069603\ \(0\)\
\-\ 167\\:\\ 0\\.017661962038069603\ \(0\)\
\-\ 190\\:\\ 0\\.017661962038069603\ \(0\)\
\-\ uveitis\\:\\ 0\\.017215095477300105\ \(0\)\
\-\ et\\:\\ 0\\.017144109951579813\ \(0\)\
\-\ discontinuous\\:\\ 0\\.016837275183605845\ \(0\)\
\-\ skip\\:\\ 0\\.016837275183605845\ \(0\)\
\-\ azathioprine\\:\\ 0\\.016837275183605845\ \(0\)\
\-\ lesions\\:\\ 0\\.01682029784076432\ \(0\)\
\-\ common\\:\\ 0\\.016443141264385272\ \(0\)\
\-\ ileitis\\:\\ 0\\.01622130844762323\ \(0\)\
\-\ smokers\\:\\ 0\\.01622130844762323\ \(0\)\
\-\ rm\\:\\ 0\\.01622130844762323\ \(0\)\
\-\ based\\:\\ 0\\.015973972364053728\ \(0\)\
\-\ ulcerations\\:\\ 0\\.015963071889638365\ \(0\)\
\-\ 10\\-20\\:\\ 0\\.015729468507765017\ \(0\)\
\-\ gut\\:\\ 0\\.015516205328868866\ \(0\)\
\-\ melena\\:\\ 0\\.015320022221825885\ \(0\)\
\-\ early\\:\\ 0\\.015319406713933519\ \(0\)\
\-\ dtpa\\:\\ 0\\.015138385035174607\ \(0\)\
\-\ enteritis\\:\\ 0\\.01496928485996149\ \(0\)\
\-\ extension\\:\\ 0\\.014952584907753204\ \(0\)\
\-\ lymphoid\\:\\ 0\\.014811102210114502\ \(0\)\
\-\ recognition\\:\\ 0\\.014811102210114502\ \(0\)\
\-\ alternating\\:\\ 0\\.014662512450760496\ \(0\)\
\-\ most\\:\\ 0\\.01450614074800056\ \(0\)\
\-\ fistulas\\:\\ 0\\.014389900600000142\ \(0\)\
\-\ lives\\:\\ 0\\.014264181741207124\ \(0\)\
\-\ fissures\\:\\ 0\\.014144598005497732\ \(0\)\
\-\ recur\\:\\ 0\\.014144598005497732\ \(0\)\
\-\ 1994\\:\\ 0\\.014144598005497732\ \(0\)\
\-\ anus\\:\\ 0\\.01403057835933378\ \(0\)\
\-\ shallow\\:\\ 0\\.013921627960875853\ \(0\)\
\-\ fold\\:\\ 0\\.013921627960875853\ \(0\)\
\-\ anywhere\\:\\ 0\\.013921627960875853\ \(0\)\
\-\ cholangitis\\:\\ 0\\.013817315180437627\ \(0\)\
\-\ bowel\\:\\ 0\\.013137027121984115\ \(0\)\
\-\ resection\\:\\ 0\\.013063312036863816\ \(0\)\
\-\ exact\\:\\ 0\\.012963622302329256\ \(0\)\
\-\ medical\\:\\ 0\\.012888773529735314\ \(0\)\
\-\ familial\\:\\ 0\\.012823528150760755\ \(0\)\
\-\ ankylosing\\:\\ 0\\.012691010451568903\ \(0\)\
\-\ \\,\\:\\ 0\\.01260659618830505\ \(0\)\
\-\ stages\\:\\ 0\\.012565291592775887\ \(0\)\
\-\ spondylitis\\:\\ 0\\.01250477048348576\ \(0\)\
\-\ sclerosing\\:\\ 0\\.012388035069296411\ \(0\)\
\-\ ulcers\\:\\ 0\\.01233168821090254\ \(0\)\
\-\ intermediate\\:\\ 0\\.012067887563372234\ \(0\)\
\-\ terminal\\:\\ 0\\.012018371123868509\ \(0\)\
\-\ planned\\:\\ 0\\.011922241924963408\ \(0\)\
\-\ mural\\:\\ 0\\.011922241924963408\ \(0\)\
\-\ far\\:\\ 0\\.011829741121083882\ \(0\)\
\-\ progress\\:\\ 0\\.011829741121083882\ \(0\)\
\-\ mouth\\:\\ 0\\.011784767741995165\ \(0\)\
\-\ include\\:\\ 0\\.011750752392305327\ \(0\)\
\-\ cholelithiasis\\:\\ 0\\.011654596601519802\ \(0\)\
\-\ erosions\\:\\ 0\\.011612698480541124\ \(0\)\
\-\ sites\\:\\ 0\\.011413321913252025\ \(0\)\
\-\ k\\:\\ 0\\.011413321913252025\ \(0\)\
\-\ 54\\:\\ 0\\.011057483653829235\ \(0\)\
\-\ mucosa\\:\\ 0\\.011057483653829235\ \(0\)\
\-\ equal\\:\\ 0\\.010960080887531407\ \(0\)\
\-\ determined\\:\\ 0\\.010928454895286537\ \(0\)\
\-\ radiologic\\:\\ 0\\.010897231792890875\ \(0\)\
\-\ mucosal\\:\\ 0\\.010805880335054523\ \(0\)\
\-\ am\\:\\ 0\\.01077617111806348\ \(0\)\
\-\ advanced\\:\\ 0\\.010717811684990641\ \(0\)\
\-\ length\\:\\ 0\\.01049735032062069\ \(0\)\
\-\ symptoms\\:\\ 0\\.010439497435775191\ \(0\)\
\-\ thus\\:\\ 0\\.010419534883575152\ \(0\)\
\-\ progression\\:\\ 0\\.010419534883575152\ \(0\)\
\-\ intravenous\\:\\ 0\\.01039413589574293\ \(0\)\
\-\ \\/\\:\\ 0\\.010344114151548796\ \(0\)\
\-\ hyperplasia\\:\\ 0\\.010319480975437272\ \(0\)\
\-\ entire\\:\\ 0\\.010295092909620683\ \(0\)\
\-\ localized\\:\\ 0\\.010199897239727881\ \(0\)\
\-\ asymmetric\\:\\ 0\\.010176665024153018\ \(0\)\
\-\ lead\\:\\ 0\\.01004171458988089\ \(0\)\
\-\ gadolinium\\:\\ 0\\.009934667865609662\ \(0\)\
\-\ dilation\\:\\ 0\\.009872614414667776\ \(0\)\
\-\ involve\\:\\ 0\\.009872614414667776\ \(0\)\
\-\ steroids\\:\\ 0\\.009852274211690581\ \(0\)\
\-\ \\%\\:\\ 0\\.009771181536009841\ \(0\)\
\-\ received\\:\\ 0\\.009733655238989967\ \(0\)\
\-\ ischemia\\:\\ 0\\.009733655238989967\ \(0\)\
\-\ involves\\:\\ 0\\.009733655238989967\ \(0\)\
\-\ incidence\\:\\ 0\\.00960215349023428\ \(0\)\
\-\ j\\:\\ 0\\.009460027858738326\ \(0\)\
\-\ distribution\\:\\ 0\\.009425747853898278\ \(0\)\
\-\ there\\:\\ 0\\.009350849679889623\ \(0\)\
\-\ affected\\:\\ 0\\.009062560322425842\ \(0\)\
\-\ metastases\\:\\ 0\\.008947873652066137\ \(0\)\
\-\ arthritis\\:\\ 0\\.008947873652066137\ \(0\)\
\-\ etiology\\:\\ 0\\.008865248511521257\ \(0\)\
\-\ radiology\\:\\ 0\\.008851744453161036\ \(0\)\
\-\ recurrent\\:\\ 0\\.008838314390012444\ \(0\)\
\-\ features\\:\\ 0\\.008838314390012444\ \(0\)\
\-\ defined\\:\\ 0\\.008824957515582139\ \(0\)\
\-\ surgical\\:\\ 0\\.008805008677703204\ \(0\)\
\-\ increase\\:\\ 0\\.008785318154686058\ \(0\)\
\-\ references\\:\\ 0\\.008707912340837285\ \(0\)\
\-\ administration\\:\\ 0\\.00869524574731169\ \(0\)\
\-\ pathology\\:\\ 0\\.008572054975789906\ \(0\)\
\-\ presenting\\:\\ 0\\.00853627360465963\ \(0\)\
\-\ treatment\\:\\ 0\\.008478514507847486\ \(0\)\
\-\ deep\\:\\ 0\\.008477774875721778\ \(0\)\
\-\ currently\\:\\ 0\\.008299443125029553\ \(0\)\
\-\ is\\:\\ 0\\.008268982035069495\ \(0\)\
\-\ colon\\:\\ 0\\.008225325759368478\ \(0\)\
\-\ unknown\\:\\ 0\\.008173724266236537\ \(0\)\
\-\ marked\\:\\ 0\\.008173724266236537\ \(0\)\
\-\ commonly\\:\\ 0\\.007903263341803043\ \(0\)\
\-\ antibiotics\\:\\ 0\\.007866951857035542\ \(0\)\
\-\ occur\\:\\ 0\\.007857957423484163\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.007822306171027353\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.007778459198598982\ \(0\)\
\-\ year\\-old\\:\\ 0\\.007693050543377981\ \(0\)\
\-\ abnormalities\\:\\ 0\\.007693050543377981\ \(0\)\
\-\ involvement\\:\\ 0\\.0076763202368328835\ \(0\)\
\-\ male\\:\\ 0\\.00757453695042879\ \(0\)\
\-\ weight\\:\\ 0\\.007507220061619768\ \(0\)\
\-\ identified\\:\\ 0\\.007483987846044905\ \(0\)\
\-\ presentation\\:\\ 0\\.007214217241399711\ \(0\)\
\-\ fever\\:\\ 0\\.007086428006254818\ \(0\)\
\-\ \\(\\:\\ 0\\.007081977708273142\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.007079883328421782\ \(0\)\
\-\ three\\:\\ 0\\.00706035350085027\ \(0\)\
\-\ \\)\\:\\ 0\\.006995467569738285\ \(0\)\
\-\ along\\:\\ 0\\.006921700678574795\ \(0\)\
\-\ radiation\\:\\ 0\\.006873164827358668\ \(0\)\
\-\ several\\:\\ 0\\.006733070675790166\ \(0\)\
\-\ between\\:\\ 0\\.006638469451530009\ \(0\)\
\-\ and\\:\\ 0\\.006617978151919796\ \(0\)\
\-\ clinical\\:\\ 0\\.006444386764867657\ \(0\)\
\-\ the\\:\\ 0\\.0064380794347276725\ \(0\)\
\-\ age\\:\\ 0\\.006374780209667418\ \(0\)\
\-\ only\\:\\ 0\\.0062975775943258224\ \(0\)\
\-\ proximal\\:\\ 0\\.006288096033595625\ \(0\)\
\-\ years\\:\\ 0\\.006150105727986476\ \(0\)\
\-\ demonstrated\\:\\ 0\\.0061456372119043316\ \(0\)\
\-\ infection\\:\\ 0\\.006088275916845115\ \(0\)\
\-\ loss\\:\\ 0\\.006079569050167744\ \(0\)\
\-\ wall\\:\\ 0\\.006066566471173398\ \(0\)\
\-\ lymphoma\\:\\ 0\\.005985780966640896\ \(0\)\
\-\ through\\:\\ 0\\.005948424064757031\ \(0\)\
\-\ following\\:\\ 0\\.005944308227698893\ \(0\)\
\-\ are\\:\\ 0\\.005710166041811773\ \(0\)\
\-\ been\\:\\ 0\\.0056980266898627235\ \(0\)\
\-\ distal\\:\\ 0\\.005694310267024575\ \(0\)\
\-\ enhancement\\:\\ 0\\.0056139430542231274\ \(0\)\
\-\ therapy\\:\\ 0\\.005599609794707385\ \(0\)\
\-\ \\:\\:\\ 0\\.005540562823483652\ \(0\)\
\-\ patients\\:\\ 0\\.005420525978838298\ \(0\)\
\-\ more\\:\\ 0\\.00523817722870629\ \(0\)\
\-\ abdominal\\:\\ 0\\.0052350961718679295\ \(0\)\
\-\ pain\\:\\ 0\\.0051157263114251705\ \(0\)\
\-\ 1\\:\\ 0\\.004983643058724772\ \(0\)\
\-\ tissue\\:\\ 0\\.0049642676187563566\ \(0\)\
\-\ associated\\:\\ 0\\.004942310200754171\ \(0\)\
\-\ were\\:\\ 0\\.004755603766396866\ \(0\)\
\-\ can\\:\\ 0\\.004750544981541837\ \(0\)\
\-\ this\\:\\ 0\\.004711456928010456\ \(0\)\
\-\ case\\:\\ 0\\.004582118708008016\ \(0\)\
\-\ 2\\:\\ 0\\.004510060040467025\ \(0\)\
\-\ after\\:\\ 0\\.004333336280904908\ \(0\)\
\-\ patient\\:\\ 0\\.004198980053511706\ \(0\)\
\-\ to\\:\\ 0\\.00418694223963712\ \(0\)\
\-\ of\\:\\ 0\\.003997679439146662\ \(0\)\
\-\ within\\:\\ 0\\.003995420118593337\ \(0\)\
\-\ has\\:\\ 0\\.003933088162976171\ \(0\)\
\-\ on\\:\\ 0\\.0035484853547324904\ \(0\)\
\-\ by\\:\\ 0\\.0034874286844237125\ \(0\)\
\-\ be\\:\\ 0\\.0032297958905488458\ \(0\)\
\-\ from\\:\\ 0\\.0031040091008681676\ \(0\)\
\-\ ct\\:\\ 0\\.00292966581713736\ \(0\)\
\-\ an\\:\\ 0\\.002896237412462573\ \(0\)\
\-\ \\.\\:\\ 0\\.0026972686740630745\ \(0\)\
\-\ was\\:\\ 0\\.0024222488289551147\ \(0\)\
\-\ no\\:\\ 0\\.0021089317419210832\ \(0\)\
\-\ in\\:\\ 0\\.0020656726967659554\ \(0\)\
\-\ a\\:\\ 0\\.0019441166755813787\ \(0\)\
\-\ with\\:\\ 0\\.0014338747069839429\ \(0\)\
